Anavex Life Sciences Corp. (AVXL) stock
AVXLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
$0.72−0.02 (-2.78%)
Close on Nov 18, 2026Market cap $66.69MP/E –Yield –
Anavex Life Sciences cash
Cash and short-term investments held at the end of each period.
Anavex Life Sciences's cash was $118.33M at Jun 30, 2026. For fiscal 2025 it was $102.58M, down 22.4% from the year before. Over ten years it grew 21.0% a year on average. The highest annual figure on record is $152.11M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $102.58M | -22.4% |
| FY2024 | Sep 30, 2024 | $132.19M | -12.5% |
| FY2023 | Sep 30, 2023 | $151.02M | +1.3% |
| FY2022 | Sep 30, 2022 | $149.16M | -1.9% |
| FY2021 | Sep 30, 2021 | $152.11M | +420.0% |
| FY2020 | Sep 30, 2020 | $29.25M | +31.8% |
| FY2019 | Sep 30, 2019 | $22.19M | -3.2% |
| FY2018 | Sep 30, 2018 | $22.93M | -16.4% |
| FY2017 | Sep 30, 2017 | $27.44M | +198.7% |
| FY2016 | Sep 30, 2016 | $9.19M | -39.9% |
| FY2015 | Sep 30, 2015 | $15.29M | +110.6% |
| FY2014 | Sep 30, 2014 | $7.26M | +2004.5% |
| FY2013 | Sep 30, 2013 | $345.07K | +2937.1% |
| FY2012 | Sep 30, 2012 | $11.36K | -91.6% |
| FY2011 | Sep 30, 2011 | $134.70K | -49.1% |
| FY2010 | Sep 30, 2010 | $264.67K | -24.6% |
| FY2009 | Sep 30, 2009 | $350.99K | – |
Quarterly cash
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | $118.33M | +17.0% |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | $127.42M | +10.1% |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | $131.75M | +9.1% |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | $102.58M | -22.4% |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | $101.16M | -27.1% |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | $115.77M | -16.9% |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | $120.78M | -16.0% |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | $132.19M | -12.5% |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | $138.76M | -10.4% |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | $139.39M | -9.2% |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | $143.77M | +0.1% |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | $151.02M | +1.3% |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | $154.82M | +1.1% |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | $153.47M | +0.1% |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | $143.62M | -5.0% |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | $149.16M | -1.9% |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | $153.20M | -2.8% |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | $153.34M | +102.1% |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | $151.15M | +219.2% |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | $152.11M | +420.0% |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | $157.56M | +470.5% |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | $75.86M | +185.6% |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | $47.36M | +72.5% |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | $29.25M | +31.8% |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | $27.62M | +30.0% |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | $26.56M | +36.5% |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | $27.46M | +32.6% |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | $22.19M | -3.2% |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | $21.25M | -17.7% |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | $19.46M | -24.2% |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | $20.72M | -26.1% |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | $22.93M | -16.4% |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | $25.83M | +4.2% |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | $25.66M | +9.9% |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | $28.05M | +32.5% |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | $27.44M | +198.7% |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | $24.79M | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | $23.35M | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | $21.16M | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | $9.19M | – |
See a number that looks wrong?